Protein Kinase Inhibitors: all 15,278 studies that test it

Page 89 of 153. Open to participants first (2,556), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of SitravatinibCompletedNCT04772612Phase 1
• Study to Compare How the Body Absorbs, Distributes and Excretes the Drug Selitrectinib (BAY2731954) Given as Two Different Tablet Formulations or as Liquid Formulations Including the Effect of Food on the Absorption, Distribution or Excretion of the Different Formulations in Healthy ParticipantsCompletedNCT04771390Phase 1
• Advanced Lung Tumor Treated by Osimertinib Plus AnlotinibCompletedNCT04770688Phase 1/2
• TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN MutationsTerminatedNCT04770246Phase 1
• Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant MetastasisStatus unknownNCT04769908Phase 2
• A Clinical Trial in Healthy Volunteers and Patients With Mild Asthma to Investigate a New Medicine (AZD4604) for the Treatment of AsthmaCompletedNCT04769869Phase 1
• Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib CapsuleCompletedNCT04768985Phase 1
• The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid TumorsStatus unknownNCT04768868Phase 1
• Tofacitinib for the Treatment of Refractory Immune-related Colitis from Checkpoint Inhibitor Therapy- TRICK StudyTerminatedNCT04768504Phase 2
• Cabozantinib Treatment in a Phase II Study for Patients With Hepatocellular Carcinoma (HCC) Refractory to PD-1 InhibitorsCompletedNCT04767906Phase 2
• Pegylated Liposomal Doxorubicin Combined With Anlotinib for Neoadjuvant Treatment of Soft Tissue SarcomaStatus unknownNCT04765228Phase 2
• Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell LymphomaActive, not recruitingNCT04765111Phase 2
• SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIsCompletedNCT04764214Phase 2
• Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid TumorsStatus unknownNCT04764084Phase 1
• Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II StudyStatus unknownNCT04764006Phase 2
• Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast CancerActive, not recruitingNCT04762979Phase 2
• First in Human Study of UCT-01-097 in Participants With Advanced Solid TumorsTerminatedNCT04761601Phase 1
• A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).WithdrawnNCT04760288Phase 3
• Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid CancerActive, not recruitingNCT04759911Phase 2
• A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric CancerActive, not recruitingNCT04757363Phase 2
• Surufatinib Renal Impairment StudyCompletedNCT04755088Phase 1
• Surufatinib Hepatic Impairment StudyCompletedNCT04755075Phase 1
• Erdafitinib for the Treatment of Patients With Castration-Resistant Prostate CancerTerminatedNCT04754425Phase 2
• Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT04752696Phase 2
• Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine TumorsActive, not recruitingNCT04750954Phase 1
• Efficacy and Safety of Tofacitinib in Patients With COVID-19 PneumoniaCompletedNCT04750317Phase 2
• First in Human Study to Evaluate the Safety and Tolerability of EYP-1901 in Patients With Wet Age Related Macular Degeneration (wAMD)CompletedNCT04747197Phase 1
• First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid TumorsTerminatedNCT04746612Phase 1
• An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib With Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients With Gastric CancerActive, not recruitingNCT04745988Phase 2
• iPSC-based Drug Repurposing for ALS Medicine (iDReAM) StudyCompletedNCT04744532Phase 1/2
• Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm TrialStatus unknownNCT04743687Phase 2
• Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04743505Phase 1/2
• Drug-drug Interaction Study of CTP-543 and Itraconazole in Healthy Adult SubjectsCompletedNCT04743414Phase 1
• A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDSStatus unknownNCT04743115Phase 1
• Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedNCT04742959Phase 1/2
• Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa & cMRI to Evaluate Cardiac Function]Active, not recruitingNCT04742777Phase 2
• Capivasertib China PK StudyCompletedNCT04742036Phase 1
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell LymphomaActive, not recruitingNCT04739813Phase 1
• Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid CancerWithdrawnNCT04739566Phase 2
• CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLCTerminatedNCT04739358Phase 1/2
• Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)CompletedNCT04739202Phase 2
• Drug-drug Interaction Study With GLPG3667 and Midazolam in Healthy SubjectsCompletedNCT04736927Phase 1
• A Phase I Study to Evaluate the Taste of Belumosudil Oral Suspensions & Assess Relative BioavailabilityCompletedNCT04735822Early Phase 1
• Rho Kinase (ROCK) Inhibitor in Tauopathies - 1Status unknownNCT04734379Phase 2
• A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)Active, not recruitingNCT04734262Phase 2
• Second-line Surufatinib Combined With Chemotherapy in Advanced CRCStatus unknownNCT04734249Phase 2
• Fruquintinib Plus Capecitabine Versus Bevacizumab Plus Capecitabine as Maintenance Therapy Following First-line Treatment for Metastatic Colorectal CancerStatus unknownNCT04733963Phase 2
• An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood CancerActive, not recruitingNCT04733534Phase 2
• A Study of SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.Status unknownNCT04733417Phase 2
• Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung CancerStatus unknownNCT04731909Not applicable
• Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid CancerWithdrawnNCT04731740Phase 2
• Combination Therapy for First Line Treatment of Advanced Cervical CancerStatus unknownNCT04731038Phase 1
• A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMMLActive, not recruitingNCT04730258Phase 1/2
• Pembrolizumab And Lenvatinib In Leptomeningeal MetastasesTerminatedNCT04729348Phase 2
• Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract CancerActive, not recruitingNCT04727996Phase 2
• Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)TerminatedNCT04726332Phase 1
• Anlotinib Combined With STUPP for MGMT Nonmethylated GlioblastomaStatus unknownNCT04725214Phase 2
• Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular CarcinomaStatus unknownNCT04724226Phase 2
• Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALLActive, not recruitingNCT04722848Phase 3
• Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable MelanomaActive, not recruitingNCT04722575Phase 2
• A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLLActive, not recruitingNCT04722172Phase 2
• Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.CompletedNCT04720131Phase 2
• Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCCStatus unknownNCT04718909Phase 2
• Anlotinib, Toripalimab and Nab-paclitaxel in Locally Advanced/Metastatic Pancreatic CancerStatus unknownNCT04718701Phase 2
• A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC)TerminatedNCT04718675Phase 1/2
• A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female ParticipantsCompletedNCT04718636Phase 1
• Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast CancerStatus unknownNCT04717531Phase 2
• PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal CancerStatus unknownNCT04715633Phase 2
• Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell CarcinomaStatus unknownNCT04714697Phase 2
• Study on the Bioavailability of SHR0302 in Healthy SubjectsCompletedNCT04712838Phase 1
• A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the BodyCompletedNCT04712396Phase 1
• First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.SuspendedNCT04711161Phase 1
• A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple SclerosisActive, not recruitingNCT04711148Phase 2
• Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIentsCompletedNCT04710628Phase 2
• Sirolimus for Retinal Astrocytic HamartomaCompletedNCT04707209Not applicable
• A Safety and Efficacy Study of Duvelisib in Relapsed/Refractory Follicular LymphomaStatus unknownNCT04707079Phase 2
• Relative Bioavailability Study and Food Effect Study of TT-00420 (Tinengotinib) Capsule and Tablet Formulations in Healthy VolunteersCompletedNCT04705922Phase 1
• Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCLStatus unknownNCT04705129Phase 2
• A Study of YY-20394 in Patients With Relapsed or Refractory Peripheral T/NK Cell LymphomaStatus unknownNCT04705090Phase 2
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingNCT04704661Phase 1
• Effect of Food on Peposertib PKCompletedNCT04702698Phase 1
• A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult SubjectsCompletedNCT04702464Phase 1
• A Study to Investigate the Effect of Severe Renal Impairment on Gilteritinib Compared to Healthy Participants With Normal Renal FunctionCompletedNCT04699877Phase 1
• Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerActive, not recruitingNCT04699838Phase 2
• Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)Status unknownNCT04699071Phase 2
• Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT04698213Phase 2
• Drug-drug Interaction Study of Evobrutinib With Midazolam in Healthy ParticipantsCompletedNCT04697511Phase 1
• Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer PatientsStatus unknownNCT04695470Phase 2
• Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 PatientsStatus unknownNCT04693026Phase 3
• Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's DiseaseActive, not recruitingNCT04691661Phase 2
• TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN LossStatus unknownNCT04690725Phase 1/2
• Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory OsteosarcomaCompletedNCT04690231Not applicable
• Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive MutationsActive, not recruitingNCT04687241Phase 3
• Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLLWithdrawnNCT04685915Phase 2
• Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) StudyActive, not recruitingNCT04685590Phase 2
• Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung CancerActive, not recruitingNCT04685070Phase 2
• Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung CancerStatus unknownNCT04684017Phase 2
• Study of HL-085 in Patients With Advanced Solid Tumor TumorsCompletedNCT04683354Phase 1
• Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLCStatus unknownNCT04683198Phase 2
• Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICCWithdrawnNCT04682249Phase 2

← Protein Kinase Inhibitors overview